You have tried the drops from the pharmacy. You take screen breaks, you have put a humidifier on your desk, and you have followed the advice of more than one professional. Yet every afternoon your eyes still burn.
By evening your vision blurs, clears for a moment when you blink, then blurs again. Reading feels like harder work than it should. The drops help for twenty minutes and then the discomfort comes straight back.
If this sounds familiar, you are not imagining it and you are not being oversensitive. It usually means your dry eye disease is being managed at the surface, but not properly understood.
For a long time, dry eye was explained as a simple plumbing problem: the eye not making enough tears. That idea is not entirely wrong, but it is far too simple. The landmark TFOS DEWS II report (Tear Film and Ocular Surface Society Dry Eye Workshop II, 2017) changed the picture completely.
Dry eye is now understood as a long-term disease of the front surface of the eye, driven by ongoing inflammation, nerve changes, and damage to the tiny glands that keep the eye healthy.
Why City Life Is Surprisingly Hard on Your Eyes
Air pollution is one of the most overlooked causes. Tiny airborne particles and chemical fumes common in busy cities make the tear film less stable and increase inflammation on the eye surface. Digital screen use has risen across every age group. When we focus on a screen, we blink far less, dropping from a normal 15 to 20 blinks a minute to as few as 5 to 7. Central heating in winter and air conditioning in summer both dry out the air, quietly working against healthy tears all day.
Dry eye also becomes far more common after the age of 50. Contact lens wear and certain eye cosmetics, especially make-up applied to the inner edge of the eyelid, can clog the eyelid's oil glands and add to the problem.
What Dry Eye Disease Actually Is
In plain English, dry eye is a long-term disease of the eye surface in which the tear film becomes unstable and too salty, the surface becomes inflamed and damaged, and the nerves that control tear production stop working normally.
There are two main types, although most people have a mixture of both.
Evaporative dry eye is the most common. It happens mainly because of meibomian gland dysfunction (MGD). The meibomian glands are tiny oil glands along the edges of your eyelids. They release a thin layer of oil that stops your tears evaporating too quickly. When these glands become blocked or shrink, the oil layer fails and tears dry up fast.
Aqueous-deficient dry eye means the watery part of the tears is reduced. This is most often linked to age-related changes in the tear glands, or to autoimmune conditions such as Sjogren's syndrome.
One surprising point: watery, runny eyes can actually be a sign of dryness. When the surface is constantly irritated, the eye produces a flood of reflex tears as a distress signal.
Symptoms Patients Often Blame on Something Else
Burning and stinging are caused by the salty, inflamed tear film irritating the sensitive nerve endings on the cornea. Grittiness comes from tiny rough patches where the surface cells have been disrupted. Vision that blurs and then clears when you blink is a direct result of an unstable tear film. Sensitivity to light reflects surface inflammation and, in more advanced cases, over-sensitive corneal nerves.
Dry eye symptoms often worsen later in the day, especially after long visual tasks. This pattern helps distinguish dry eye from allergic eye disease, which usually flares with specific triggers like pollen or dust.
Why Drops Alone Are Only Part of the Answer
Artificial tears have a place, but they address only one part of a many-sided disease. They do not calm the underlying inflammation, and they do not repair the oil glands. Drops containing preservatives, used several times a day over a long period, can themselves irritate an already sensitive surface. Without a proper eye-surface examination, the real cause stays untreated and patients cycle through product after product with little lasting improvement.
Inflammation drives dry eye disease rather than simply resulting from it. An unstable tear film makes the surface too salty, which switches on inflammation, which damages the surface cells, which makes the tear film even more unstable. Blepharitis (inflammation of the eyelid edges) is closely tied to MGD. Treating a dry eye while ignoring blepharitis is a bit like mopping the floor without a disinfectant. The bugs still remain.
What a Proper Dry Eye Assessment Involves
A specialist dry eye assessment uses objective tests that many patients have never had. Slit-lamp examination studies the eyelid edges, surface, and cornea in fine detail. Tear film assessment measures how quickly the tear film breaks down. Meibomian gland imaging is an infrared scan that photographs the oil glands inside the eyelids, revealing whether any have shrunk or been lost. Surface staining uses harmless dyes that highlight areas of damage invisible to the naked eye.
Treatments That Go Beyond the Drops
1. Lifestyle Modifications The TFOS Lifestyle Report 2023 identifies lifestyle modification as the essential first step.
- prolonged screen use, low humidity, wind exposure —
- dietary adjustments
- cosmetic habits,
- environmental changes.
These interventions alone can meaningfully reduce DED signs and symptoms.
2. Warm Compresses and Manual Expression Warm compresses remain the cornerstone of MGD management, melting inspissed meibum to facilitate manual gland expression, improve lipid layer thickness, and restore gland function. Should be performed daily and reviewed at each appointment.
3. Device-Based Thermal Treatments
- LipiFlow — a single treatment improves meibomian secretions and symptoms, sustained at 6 months
- MiBoFlo + manual expression — demonstrated superior subjective and objective outcomes versus automated LipiFlow at 6 months
- Blephasteam — moist latent heat goggle.
All device-based treatments should be followed by immediate manual gland expression to maximise benefit.
4. Intense Pulsed Light (IPL) Strongly supported by multiple RCTs showing improvements in tear quality and increased meibomian gland secretions. IPL combined with immediate manual expression is positioned as the key intervention for moderate-to-severe MGD.
5. Low-Level Light Therapy (LLLT) A non-thermal photobiomodulation option. Included in DEWS III as a useful alternative for patients unsuitable for IPL, and as a maintenance therapy between IPL sessions.
6. Nutritional Supplementation
Omega-3 fatty acid supplementation significantly improved tear quality and with meibomian gland quality and expressibility.
References
- Craig JP, Nichols KK, Akpek EK, et al., 'TFOS DEWS II definition and classification report', The Ocular Surface, 15(3), 2017, pp. 276-283.
- Bron AJ, de Paiva CS, Chauhan SK, et al., 'TFOS DEWS II pathophysiology report', The Ocular Surface, 15(3), 2017, pp. 438-510.
- Torricelli AAM, Novaes P, Matsuda M, et al., 'Correlation between signs and symptoms of ocular surface dysfunction and tear osmolarity with ambient levels of air pollution in a large metropolitan area', Cornea, 32(4), 2013, pp. e11-e15.
- Portello JK, Rosenfield M and Chu CA, 'Blink rate, incomplete blinks and computer vision syndrome', Optometry and Vision Science, 90(5), 2013, pp. 482-487.
- Stapleton F, Alves M, Bunya VY, et al., 'TFOS DEWS II epidemiology report', The Ocular Surface, 15(3), 2017, pp. 334-365.
- Lemp MA, Crews LA, Bron AJ, et al., 'Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study', Cornea, 31(5), 2012, pp. 472-478.
- Jones L, Downie LE, Korb D, et al., 'TFOS DEWS II management and therapy report', The Ocular Surface, 15(3), 2017, pp. 575-628.
- Pflugfelder SC and de Paiva CS, 'The pathophysiology of dry eye disease: what we know and future directions for research', Ophthalmology, 124(11S), 2017, pp. S4-S13.
- Cote S, Zhang AC, Ahmadzai V, et al., 'Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction', Cochrane Database of Systematic Reviews, Issue 3, 2020, CD013559.
- Vivino FB, Bunya VY, Massaro-Giordano G, et al., 'Sjogren's syndrome: an update on disease pathogenesis, clinical manifestations and treatment', Clinical Immunology, 203, 2019, pp. 81-93.
- National Institute for Health and Care Excellence (NICE), Dry Eye Disease - Clinical Knowledge Summary, NICE, London, available at: cks.nice.org.uk [accessed May 2026].
- General Medical Council, Good Medical Practice, GMC, London, 2024, available at: gmc-uk.org [accessed May 2026].
